KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Prepaid Assets (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Prepaid Assets data on record, last reported at $10.8 million in Q4 2025.

  • For Q4 2025, Prepaid Assets fell 42.53% year-over-year to $10.8 million; the TTM value through Dec 2025 reached $10.8 million, down 42.53%, while the annual FY2025 figure was $10.8 million, 42.53% down from the prior year.
  • Prepaid Assets reached $10.8 million in Q4 2025 per PACB's latest filing, down from $11.5 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $18.8 million in Q4 2024 and bottomed at $5.6 million in Q1 2021.
  • Average Prepaid Assets over 5 years is $12.3 million, with a median of $12.6 million recorded in 2022.
  • Peak YoY movement for Prepaid Assets: soared 128.58% in 2021, then tumbled 42.53% in 2025.
  • A 5-year view of Prepaid Assets shows it stood at $7.4 million in 2021, then surged by 39.15% to $10.3 million in 2022, then soared by 65.61% to $17.0 million in 2023, then rose by 10.22% to $18.8 million in 2024, then crashed by 42.53% to $10.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Prepaid Assets were $10.8 million in Q4 2025, $11.5 million in Q3 2025, and $12.3 million in Q2 2025.